Immunoglobulin therapy for the treatment of insulin resistance and type 2 diabetes

Stanford researchers in the Snyder lab have discovered and developed an innovative immunoglobulin modality for the treatment of insulin resistance and type 2 diabetes. Type 2 diabetes affects millions of people worldwide and can lead to a myriad of severe and life-threatening complications. Current treatments for managing insulin resistance and type 2 diabetes, such as metformin, carry the risk of significant side-effects up to and including dangerous hypoglycemia. Chronic inflammation is a common feature of insulin resistance, however the role that the immune system plays in its development is not fully understood.

This new immunoglobin therapy has shown significant improvements to insulin sensitivity and blood glucose metabolism *in vivo*, promising a new and effective therapeutic strategy for treating insulin resistance and type 2 diabetes.

Applications

- Insulin Resistance
- Type 2 Diabetes

Advantages

- Novel therapeutic strategy
- High specificity
- Current treatments carry risk of severe side-effects

Patents

- Published Application: <u>WO2022104394</u>
- Published Application: 20240002474

Innovators

- Michael Snyder
- Andrew Lipchik
- Justin Annes
- Sooyeon Lee
- Anil Narasimha

Licensing Contact

Hyunjin Kim

Licensing Manager, Life Sciences

<u>Email</u>